Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective treatment for Parkinson's disease, but long-term l-DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions of l-DOPA. MDMA is composed of two enantiomers with different pharmacological profiles; here, we describe a novel enantiospecific synthesis of the two enantiomers and expand on the previous characterization of their pharmacology.R-MDMA (rectus-MDMA) is relatively selective for 5-HT 2A receptors, whereas S-MDMA (sinister-MDMA) inhibits both serotonin (SERT) and dopamine transporters (DAT; SERT/DAT ratio of 10 to 1).R- or S-MDMA (1, 3, and 10 mg/kg, s.c.) was administered in combination with l-DOPA (15 mg/kg, s.c.) to six female common marmosets (Callithrix jacchus) rendered parkinsonian by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) administration. Motor disability, including parkinsonism and dyskinesia, and duration of antiparkinsonian benefit (ON-time) were evaluated. After the administration of R-MDMA (3 and 10 mg/kg), the severity of peak-dose dyskinesia was decreased (by 33 and 46%, respectively;p< 0.05); although total ON-time was unchanged (∼220 min), the duration of ON-time with disabling dyskinesia was decreased by 90 min when compared to l-DOPA alone (69% reduction;p< 0.05).S-MDMA (1 mg/kg) increased the total ON-time by 88 min compared to l-DOPA alone (34% increase;p< 0.05), though dyskinesia were exacerbated. These data suggest that racemic MDMA exerts simultaneous effects, reducing dyskinesia and extending ON-time, by 5-HT 2A antagonism and SERT-selective mixed monoamine uptake inhibition, which arise from its R and S enantiomers, respectively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050 · cited 1×
“However, with increased duration of therapy, motor complications develop and afflict 95% of patients after 15 years (Hely et al., 2005).”
BackgroundNew Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731 · cited 1×
“Indeed, after its binding with monoamine transporters, MDMA inhibits monoamine uptake and reverses transport direction, promoting neurotransmitter release (Fleckenstein et al., 2007) and depleting presynaptic vesicles (Mlinar and Corradetti, 2003).”
BackgroundSerotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
Ballanger, B., Strafella, A. P., van Eimeren, T., Zurowski, M., Rusjan, P. M., Houle, S., & Fox, S. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.35 · Cited by 266 · cited 1×
“The data are also in accordance with two recent anatomical studies which found increased 5-HT2A receptor levels in the temporal cortex of PD patients with visual hallucinations (Ballanger et al., 2010; Huot et al., 2010b).”
ResultSelf-citationHuot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153 · cited 2×
“The data are also in accordance with two recent anatomical studies which found increased 5-HT2A receptor levels in the temporal cortex of PD patients with visual hallucinations (Ballanger et al., 2010; Huot et al., 2010b).”
BackgroundResultSelf-citation
Cited by
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Self-citationEffects of Schedule I drug laws on neuroscience research and treatment innovation
Nutt, D. J., King, L. A., & Nichols, D. E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3530 · Cited by 337
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
Self-citationPsychedelic-inspired drug discovery using an engineered biosensor
Dong, C., Ly, C., Dunlap, L. E., Vargas, M. V., Sun, J., Hwang, I.-W., Azinfar, A., Oh, W. C., Wetsel, W. C., Olson, D. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.043 · Cited by 213
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Self-citation
Metadata
- Authors
- Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M. J., & Brotchie, J. M.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2011-05-11
- Volume
- 31
- Issue
- 19
- Pages
- 7190-7198
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2152250507
- Cited by
- 81
- References
- 4
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time. https://app.cochat.ai/papers/10.1523/jneurosci.1171-11.2011
- The paper
- Huot, P., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, M. G., Fox, S. H., Piggott, M. J., & Brotchie, J. M. (2011). Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate:R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1171-11.2011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.